Cometriq (cabozantinib) — Medica
Differentiated thyroid carcinoma refractory to radioactive iodine therapy
Initial criteria
- age ≥ 12 years
- differentiated thyroid carcinoma (e.g., papillary, follicular, or oncocytic)
- disease refractory to radioactive iodine therapy
- patient has tried Lenvima (lenvatinib) or sorafenib
Approval duration
1 year